- Home
- ATNM vs MSAI Comparison
ATNM vs MSAI Comparison
Compare ATNM & MSAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- MSAI
- Stock Information
- Founded
- ATNM 2000
- MSAI 1995
- Country
- ATNM United States
- MSAI United States
- Employees
- ATNM N/A
- MSAI N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- MSAI
- Sector
- ATNM Health Care
- MSAI
- Exchange
- ATNM Nasdaq
- MSAI Nasdaq
- Market Cap
- ATNM 56.5M
- MSAI 50.2M
- IPO Year
- ATNM N/A
- MSAI N/A
- Fundamental
- Price
- ATNM $1.22
- MSAI $1.61
- Analyst Decision
- ATNM Strong Buy
- MSAI Strong Buy
- Analyst Count
- ATNM 5
- MSAI 1
- Target Price
- ATNM $10.20
- MSAI $8.00
- AVG Volume (30 Days)
- ATNM 319.6K
- MSAI 42.0K
- Earning Date
- ATNM 11-14-2024
- MSAI 11-12-2024
- Dividend Yield
- ATNM N/A
- MSAI N/A
- EPS Growth
- ATNM N/A
- MSAI N/A
- EPS
- ATNM N/A
- MSAI N/A
- Revenue
- ATNM $81,000.00
- MSAI $7,616,000.00
- Revenue This Year
- ATNM $186.10
- MSAI $127.29
- Revenue Next Year
- ATNM $19,248.94
- MSAI $229.75
- P/E Ratio
- ATNM N/A
- MSAI N/A
- Revenue Growth
- ATNM N/A
- MSAI 30.50
- 52 Week Low
- ATNM $1.16
- MSAI $1.40
- 52 Week High
- ATNM $10.24
- MSAI $14.00
- Technical
- Relative Strength Index (RSI)
- ATNM 35.90
- MSAI 42.22
- Support Level
- ATNM $1.16
- MSAI $1.40
- Resistance Level
- ATNM $1.29
- MSAI $1.70
- Average True Range (ATR)
- ATNM 0.09
- MSAI 0.13
- MACD
- ATNM 0.00
- MSAI 0.01
- Stochastic Oscillator
- ATNM 21.54
- MSAI 45.00
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About MSAI Infrared Cameras Holdings Inc.
MultiSensor AI Holdings Inc develops and sells a full-stack, AI-driven predictive maintenance solution. MultiSensor AI's SmartIR and associated software platforms, powered by AWS, leverage MSAI-built thermal imaging, visible imaging, acoustic imaging, vibration, and laser sensing devices for condition-based monitoring of critical mechanical and electrical assets and manufactured outputs. Its solutions are deployed by organizations to protect critical assets across a wide range of industries including distribution & logistics, manufacturing, utilities, and oil & gas. MSAI designs and manufactures digital thermal sensing solution platforms with edge and cloud-based software. The company generates the majority of its revenue from product sales.